Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; A preliminary clinical study

Journal of B.U.ON.

Volumn 16, Issue 4, 2011, Pages 759-764

  Duman, Berna Bozkurt ^a   Kara, B ^b   Kara, I Oguz ^a   Demiryurek, H ^c   Aksungur, E ^c  

^a CUKUROVA UNIVERSITY   (Turkey)

^b Adana Numune Government Hospital   (Turkey)

^c CUKUROVA UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Hand foot syndrome; Hepatocellular carcinoma; Sorafenib; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; DOXORUBICIN; SORAFENIB;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; GOLD STANDARD; HAND FOOT SYNDROME; HUMAN; LIVER CELL CARCINOMA; MALE; MULTIPLE CYCLE TREATMENT; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; FEMALE; HAND-FOOT SYNDROME; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; VITAMIN E;

EID: 84855431211     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Liu L, Cao Y, Chen C et al. Sorafenib blocks the RAF/MEK/ ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-11858. (Pubitemid 46094197)
2. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
3. Ratain MJ, Eisen T, Stadler WM et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-2512. (Pubitemid 46630627)
4. Rara IO, Sahin B, Erkisi M. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 2006; 15: 414-424.
5. Lipworth AD, Robert C, Zhu AX. Hand-Foot Syndrome (Hand-Foot Skin Reaction, Palma Plantar Erythrodysesthesia): Focus on Sorafenib and Sunitinib. Oncology 2009; 77: 257-271 (Review).
6. Burgdorf WH, Gilmore WA, Ganick RG. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med 1982; 97: 61-62. (Pubitemid 12091283)
7. Lokich J, Moore C. Chemotherapy associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984; 101: 789-800.
8. MetaAnalysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16: 3537-3541.
9. Chu D, Lacouture ME, Weiner E, Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a metaanalysis. Clin Genitourin Cancer 2009; 7: 11-19.
10. Lee WJ, Lee JL, Chang SE et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009; 161: 1045-1051.
11. Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000; 1: 225-234 (Review).
12. Lacouture ME, Wu S, Robert C et al. Evolving strategies for the management of hand-foot skin reaction associated with the multi-targeted kinase inhibitors sorafenib and sunitinib. The Oncologist 2008; 13: 1001-1011.
13. Grene F, Page D, Fleming I, Fritz A. AJJC Cancer Staging Manual (6th Edn). New York, NY: Springer-Verlag, 2002.
14. Pugh RN. Pugh's grading in the classification of liver decompensation. Gut 1992; 33: 1583.
15. Strumberg D, Awada A, Hirte H et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumors: Is rash associated with treatment outcome? Eur J Cancer 2006; 42: 548-556. (Pubitemid 43227936)
16. Escudier B, Eisen T, Stadler WM et al. TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134. Erratum in: N Engl J Med 2007; 357: 203. (Pubitemid 46089673)
17. Rong HH, Cowen EW, Azad NS, Dahut W, Gutierrez M, Turner ML. Keratoacanthomas associated with sorafenib therapy. J Am Acad Dermatol 2007; 56: 171-172.
18. Chung NM, Gutierrez M, Turner ML. Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib. Arch Dermatol 2006; 142: 1510-1511. (Pubitemid 44790655)
19. Azad NS, Aragon-Ching JB, Dahut WL et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination of anti-vascular endothelial growth factor therapy. Clin Cancer Res 2009; 15: 1411-1416.
20. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006; 42: 3127-3139. (Pubitemid 44869016)
21. Autier J, Mateus C, Wechsler J, Spatz A, Robert C. Cutaneous side effects of sorafenib and sunitinib. Ann Dermatol Venereol 2008; 135: 148-53; quiz 147, 154 (Review).
22. Crider MR, Jansen J, Norins AL, McHale MS. Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation. Arch Dermatol 1986; 122: 1023-1027. (Pubitemid 16053116)
23. Baack BR, Bergdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol 1991; 24: 457-461 (Review).
24. Horwitz LJ, Dreizen S. Acral erythemas induced by chemotherapy and graft-versus-host disease in adults with hematogeneous malignancies. Cutis 1990; 46: 397-404.
25. Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Raranes C, Herzig GP. High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62: 361-369. (Pubitemid 13036086)
26. Demirçay Z, Gürbüz O, Alpdoǧan TB et al. Chemotherapy-induced acral erythema in leukemic patients: a report of 15 cases. Int J Dermatol 1997; 36: 593-598. (Pubitemid 27386478)
27. Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy 2007; 27: 1125-1144 (Review). (Pubitemid 47173659)
28. Hilger RA, Rredtke S, Scheulen ME, Seeber S, Strumberg D. Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006. Int J Clin Pharmacol Ther 2004; 42: 648-649.
29. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25-35. (Pubitemid 46630490)
30. Heo YS, Chang HM, Kim TW et al. Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. J Clin Pharmacol 2004; 44: 1166-1172. (Pubitemid 39202461)
31. Comandone A, Bretti S, La Grotta G et al. Palmar-plantar erythrodysesthesia syndrome associated with 5-fluorouracil treatment. Anticancer Res 1993; 13(5C): 1781-1783. (Pubitemid 24008102)
32. Chu DT, Lacouture ME, Fillos T, Wu S. Risk of sorafenib-induced hand-foot skin reaction in patients with renal cell carcinoma and non renal cell malignancy. San Francisco, ASCO Genitourinary Cancer Symposium, 2008, abstr 3777.
33. Keohan M, D'Adamo D, Quin L et al. Analysis of toxicity in a phase II study of sorafenib in soft tissue sarcoma (STS). J Clin Oncol 2007; 25(Suppl): abstr 10061.
34. Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 2002; 20: 3-10. (Pubitemid 34151055)
35. Rampmann KR, Graves T, Rogers SD. Acral erythema secondary to high-dose cytosine arabinoside with pain worsened by cyclosporine infusions. Cancer 1989; 63: 2482-2485. (Pubitemid 19152759)
36. Robert C, Soria JC, Spatz A et al. T. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005; 6: 491-500 (Review). (Pubitemid 40903630)
37. Havlik RJ. Vitamin E and wound healing. Plastic Surgery Educational Foundation DATA Committee. Plast Reconstr Surg 1997; 100: 1901-1912.
38. Greenwald DP, Sharzer LA, Padawer J et al. Zone II flexor tendon repair: effects of vitamins A, E, beta-carotene. J Surg Res 1990; 49: 98-102. (Pubitemid 20221422)
39. Ehrlich HP, Tarver H, Hunt TR. Inhibitory effects of vitamin E on collagen synthesis and wound repair. Ann Surg 1972; 175: 235-240.
40. Galeano M, Torre V, Deodato B et al. Raxofelast, a hydrophilic vitamin E-like antioxidant, stimulates wound healing in genetically diabetic mice. Surgery 2001; 129: 467-477. (Pubitemid 32289898)
41. Taren DL, Chvapil M, Weber CW. Increasing the breaking strength of wounds exposed to preoperative irradiation using vitamin E supplementation. Int J Vitam Nutr Res 1987; 57: 133-137.
42. Ragoma P, Burger SN, Seifter E et al. The effect of vitamin E on experimentally induced peritoneal adhesions in mice. Arch Surg 1985; 120: 949-951. (Pubitemid 15040895)
43. Yamamoto D, Yamamoto C, Iwase S, Ruroda Y, Odagiri H, Naguma Y. Efficacy of Vitamin E Treatment for Hand-foot Syndrome in Patients Receiving Capecitabine. Breast Care 2010; 5: 415-416.